Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B

Purpose To study the changes in serum ferritin levels in lamivudine (LAM)-treated patients with chronic hepatitis and liver cirrhosis type B and determine whether successful treatment with LAM results in a reduction of serum ferritin levels. Methods Thirty patients with chronic hepatitis B virus (HB...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology international 2008-09, Vol.2 (3), p.382-387, Article 382
Main Authors: Ohkoshi, Shogo, Yoshimura, Akira, Yamamoto, Satoshi, Yano, Masahiko, Kurita, So, Yamazaki, Kazuhide, Aoki, Yo-hei, Yamagiwa, Satoshi, Wakabayashi, Hiroto, Sugiyama, Motoya, Takahashi, Tohru, Ishikawa, Tohru, Matsuda, Yasunobu, Ichida, Takafumi, Kamimura, Tomoteru, Aoyagi, Yutaka
Format: Article
Language:English
Subjects:
Anemia
Colorectal Surgery
Hepatitis
Hepatitis B virus
Hepatology
Iron
Liver cirrhosis
Medicine
Medicine & Public Health
Original
Original Article
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To study the changes in serum ferritin levels in lamivudine (LAM)-treated patients with chronic hepatitis and liver cirrhosis type B and determine whether successful treatment with LAM results in a reduction of serum ferritin levels. Methods Thirty patients with chronic hepatitis B virus (HBV) infection were followed prospectively during their treatment with LAM for 12 months. Serum HBV DNA, ferritin levels, and emergence of YMDD mutants were monitored. A case of severe liver cirrhosis with hepatic hemosiderosis that was treated successfully with LAM also is shown as a representative case. Results Serum alanine aminotransferase and ferritin levels decreased significantly more in the patients treated with LAM without YMDD mutants ( n  = 23) than those with mutants ( n  = 7). Hepatic hemosiderosis along with serum iron markers improved greatly in the representative patient. Conclusion Successful treatment with LAM may reduce serum ferritin levels and improve hepatic siderosis in a subset of patients with chronic HBV infection.
ISSN:1936-0533
1936-0541
DOI:10.1007/s12072-008-9084-z